Fresenius Medical Care (NYSE:FMS) Posts Earnings Results, Beats Expectations By $0.07 EPS

Fresenius Medical Care (NYSE:FMS) issued its quarterly earnings results on Tuesday. The company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.41 by $0.07, Zacks reports. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%.

Fresenius Medical Care Stock Up 0.8 %

FMS stock opened at $23.51 on Tuesday. Fresenius Medical Care has a 12 month low of $17.93 and a 12 month high of $25.25. The firm has a 50 day simple moving average of $23.39 and a 200 day simple moving average of $21.74. The firm has a market cap of $13.79 billion, a PE ratio of 19.52, a P/E/G ratio of 0.76 and a beta of 0.93. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02.

Analyst Ratings Changes

A number of research firms have issued reports on FMS. Berenberg Bank initiated coverage on Fresenius Medical Care in a research note on Wednesday, November 6th. They issued a “buy” rating and a $25.60 target price on the stock. Truist Financial boosted their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Finally, StockNews.com upgraded Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.